Interventional Oncology Market Growth, Size, Trends ,Analysis and Segment Forecast to 2034
Global Interventional Oncology Market Growth, Size, Trends Analysis- By Technique, By Procedure, By Applications, By End-use- Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Oct-2025 | Report ID: MEDE2571 | Pages: 1 - 244 | Formats*: |
| Category : Medical Devices | |||
Interventional Oncology Market Introduction and Overview
According to SPER Market Research, the Global Interventional Oncology Market is estimated to reach USD 6.29 billion by 2034 with a CAGR of 8.83%.
The report includes an in-depth analysis of the Global Interventional Oncology Market, including market size and trends, product mix, Applications, and supplier analysis. The Global Interventional Oncology Market was valued at USD 2.7 billion in 2024, and it is expected to rise at a 8.83% CAGR from 2025 to 2034. The interventional oncology market is growing due to the rising global cancer patient population, driven by aging, lifestyle factors, and environmental risks. Common cancers, including liver, lung, kidney, and colorectal, are often detected at advanced stages where conventional surgery is less effective. This has increased demand for minimally invasive, image-guided treatments such as transarterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), and percutaneous ablation, offering palliative and curative solutions, especially for patients with inoperable or metastatic tumors.
By Technique Insights
In 2024, ablation therapies led the market with the largest revenue share, driven by the rising demand for minimally invasive cancer treatments like radiofrequency, microwave, cryoablation, and laser ablation. These methods effectively target tumors while minimizing damage to surrounding tissues, offering quicker recovery and fewer complications compared to traditional treatments. Similarly, embolization therapies, which block tumor blood supply, are gaining traction, especially for liver cancer, due to shorter hospital stays, lower costs, and growing preference for patient-centric, cost-effective treatment options.
By Procedure Insights
In 2024, the vascular interventions segment held the largest revenue share, driven by procedures like transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and percutaneous transhepatic biliary drainage (PTBD). Growth is fueled by advancements in minimally invasive techniques, rising liver cancer cases, and improved imaging and catheter-based delivery systems. Meanwhile, the tumor ablation segment is expected to grow rapidly, led by radiofrequency, microwave, cryoablation, and laser techniques, offering precise, minimally invasive cancer treatment options and gaining adoption among healthcare providers for better patient outcomes.
By Applications Insights
The increasing worldwide incidence of hepatocellular carcinoma (HCC) contributed to the liver cancer segment's dominance of the interventional oncology market in 2024. Minimally invasive treatments like radiofrequency ablation (RFA), trans arterial chemoembolization (TACE), and microwave ablation are widely used to improve patient outcomes, supported by increasing adoption of image-guided procedures. Meanwhile, the lung cancer segment is growing rapidly due to rising cases and advancements in microwave ablation, cryoablation, and image-guided techniques. Investments by key players like Boston Scientific and AngioDynamics are further accelerating market expansion.
By End-User Insights
Due to the sophisticated infrastructure and ability to carry out interventional oncology operations including tumour embolization and ablation, hospitals accounted for the biggest revenue share in 2024. Favorable reimbursement policies further support hospital-based treatments, enhancing patient accessibility. For example, Singapore General Hospital received global recognition for interventional oncology care in 2021. Meanwhile, the specialty clinics segment is projected to grow rapidly due to their increasing number, personalized care, and dedicated expertise, making them a preferred choice for patients seeking timely, high-quality cancer treatments.
Regional Insights
In 2024, North America dominated the interventional oncology market, driven by the presence of leading industry players, advanced healthcare infrastructure, rising healthcare expenditure, and growing awareness of minimally invasive procedures. A high incidence of cancer and favourable regulations further accelerate market expansion. According to the Canadian Cancer Society’s 2023 report, many numbers of people were expected to be diagnosed with cancer, making it the leading cause of death. This growing disease burden continues to drive demand for innovative interventional oncology solutions across the region.
Market Competitive Landscape
The interventional oncology (IO) market is highly competitive, with key players like Medtronic, Boston Scientific, and Siemens Healthineers focusing on mergers, partnerships, and innovations to advance ablation, embolization, and AI-driven imaging solutions. Global market expansion is being driven by rising cancer prevalence and rising demand for minimally invasive therapies. However, challenges such as high equipment costs and the need for skilled professionals act as restraints. Regional strengths and continuous technological advancements further shape the market’s evolving competitive landscape.
Recent Developments:
In December 2024, AngioDynamics received FDA 510(k) clearance for its NanoKnife System, a non-thermal and radiation-free technology designed to ablate prostate tissue, offering a minimally invasive treatment option for prostate cancer patients.
In February 2024, Profound Medical partnered with Siemens Healthineers to integrate the TULSA-PRO system with Siemens' MAGNETOM Free.Max MRI scanner, aiming to deliver a comprehensive solution for MRI-guided prostate therapy and improve treatment precision.
In September 2024, Care.ai, a business that specialises in AI-powered virtual care, smart room technologies, and ambient intelligence solutions, was fully acquired by Stryker Corporation. This acquisition enhances Stryker’s healthcare IT offerings and connected medical device portfolio, enabling smarter, real-time patient care.
In November 2023, Terumo Corporation India unveiled LifePearl and Occlusafe to enhance liver cancer therapy options. Occlusafe supports embolization procedures, while LifePearl delivers drug-eluting beads for targeted chemotherapy, improving patient outcomes and expanding therapeutic possibilities.
In August 2022, Boston Scientific Corporation acquired Obsidio, Inc., boosting its interventional oncology and embolization portfolio with Gel Embolic Material (GEM) technology, providing an innovative treatment option for physicians and patients.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Technique, By Procedure, By Applications, By End-use |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | AngioDynamics Inc., Boston Scientific Corporation, Cook Medical, GE Healthcare, Johnson & Johnson (Ethicon), Medtronic plc, Profound Medical, Siemens Healthineers, Stryker Corporation, and Teleflex Incorporated. |
Key Topics Covered in the Report
- Global Interventional Oncology Market Size (FY’2021-FY’2034)
- Overview of Global Interventional Oncology Market
- Segmentation of Global Interventional Oncology Market By Technique (Ablation Therapies, Embolization Therapies)
- Segmentation of Global Interventional Oncology Market By Procedure (Tumor Ablation, Tumor Biopsy, Vascular Intervention, Palliative Care)
- Segmentation of Global Interventional Oncology Market By Applications (Liver Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer, Breast Cancer)
- Segmentation of Global Interventional Oncology Market By End-Use (Hospitals, Specialty Clinics)
- Statistical Snap of Global Interventional Oncology Market
- Expansion Analysis of Global Interventional Oncology Market
- Problems and Obstacles in Global Interventional Oncology Market
- Competitive Landscape in the Global Interventional Oncology Market
- Details on Current Investment in Global Interventional Oncology Market
- Competitive Analysis of Global Interventional Oncology Market
- Prominent Players in the Global Interventional Oncology Market
- SWOT Analysis of Global Interventional Oncology Market
- Global Interventional Oncology Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs2.2.Market size estimation2.2.1.Top-down and Bottom-up approach2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats5.2.PESTEL Analysis5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape5.3.PORTERs Five Forces5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Interventional Oncology Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Interventional Oncology Market
7.Global Interventional Oncology Market, By Technique (USD Million) 2021-2034
7.1.Ablation Therapies7.1.1.Radiofrequency Ablation (RFA)7.1.2.Microwave Ablation (MWA)7.1.3.Cryoablation7.1.4.Laser Ablation7.1.5.Irreversible Electroporation (IRE)7.2.Embolization Therapies7.2.1.Transarterial Chemoembolization (TACE)7.2.2.Transarterial Radioembolization (TARE)7.3.Biopsy Techniques7.3.1.Core Needle Biopsy7.3.2.Fine Needle Aspiration (FNA)7.4.Targeted Therapy Delivery Systems7.4.1.Drug-Eluting Beads7.4.2.Radioembolization7.4.3.Drug-Eluting Stents7.4.4.Injectable Hydrogels and Nanoparticles7.4.5.Other Targeted Therapy Systems7.5.Image-Guided Procedures7.5.1.Ultrasound Guidance7.5.2.CT Scan Guidance7.5.3.MRI Guidance7.5.4.Fluoroscopy Guidance
8.Global Interventional Oncology Market, By Procedure (USD Million) 2021-2034
8.1.Tumor Ablation8.2.Tumor Biopsy8.3.Vascular Interventions8.4.Palliative Care
9.Global Interventional Oncology Market, By Applications (USD Million) 2021-2034
9.1.Liver Cancer9.2.Lung Cancer9.3.Kidney Cancer9.4.Prostate Cancer9.5.Breast Cancer9.6.Other Cancer
10.Global Interventional Oncology Market, By End-Use (USD Million) 2021-2034
10.1.Hospitals10.2.Specialty Clinics
11.Global Interventional Oncology Market, (USD Million) 2021-2034
11.1.Global Interventional Oncology Market Size and Market Share
12.Global Interventional Oncology Market, By Region, (USD Million) 2021-2034
12.1.Asia-Pacific12.1.1.Australia12.1.2.China12.1.3.India12.1.4.Japan12.1.5.South Korea12.1.6.Rest of Asia-Pacific12.2.Europe12.2.1.France12.2.2.Germany12.2.3.Italy12.2.4.Spain12.2.5.United Kingdom12.2.6.Rest of Europe12.3.Middle East and Africa12.3.1.Kingdom of Saudi Arabia12.3.2.United Arab Emirates12.3.3.Qatar12.3.4.South Africa12.3.5.Egypt12.3.6.Morocco12.3.7.Nigeria12.3.8.Rest of Middle-East and Africa12.4.North America12.4.1.Canada12.4.2.Mexico12.4.3.United States12.5.Latin America12.5.1.Argentina12.5.2.Brazil12.5.3.Rest of Latin America
13.Company Profile
13.1.AngioDynamics Inc.13.1.1.Company details13.1.2.Financial outlook13.1.3.Product summary13.1.4.Recent developments13.2.Boston Scientific Corporation13.2.1.Company details13.2.2.Financial outlook13.2.3.Product summary13.2.4.Recent developments13.3.Cook Medical13.3.1.Company details13.3.2.Financial outlook13.3.3.Product summary13.3.4.Recent developments13.4.GE Healthcare13.4.1.Company details13.4.2.Financial outlook13.4.3.Product summary13.4.4.Recent developments13.5.Johnson & Johnson (Ethicon)13.5.1.Company details13.5.2.Financial outlook13.5.3.Product summary13.5.4.Recent developments13.6.Medtronic plc13.6.1.Company details13.6.2.Financial outlook13.6.3.Product summary13.6.4.Recent developments13.7.Profound Medical13.7.1.Company details13.7.2.Financial outlook13.7.3.Product summary13.7.4.Recent developments13.8.Siemens Healthineers13.8.1.Company details13.8.2.Financial outlook13.8.3.Product summary13.8.4.Recent developments13.9.Stryker Corporation13.9.1.Company details13.9.2.Financial outlook13.9.3.Product summary13.10.Teleflex Incorporated13.10.1.Company details13.10.2.Financial outlook13.10.3.Product summary13.10.4.Recent developments13.11.Others
14.Conclusion
15.List of Abbreviations
16.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Interventional Oncology Marketis projected to reach USD 6.29 by 2034, growing at a CAGR of 8.83% during the forecast period.
Interventional Oncology Marketsize from 2025. The Market is expected to reach USD 6.29 by 2034, at a CAGR of 8.83% during the forecast period.
Interventional Oncology MarketCAGR of 6.29 % during the forecast period.
You can get the sample pages by clicking the link - Click Here
Interventional Oncology Marketsize is USD 8.83from 2025 to 2034.
Interventional Oncology Marketcovered By Technique, By Procedure, By Applications, By End-use
The North America is anticipated to have the highest Market share in the Interventional Oncology Market .
AngioDynamics Inc., Boston Scientific Corporation, Cook Medical, GE Healthcare, Johnson & Johnson (Ethicon), Medtronic plc, Profound Medical, Siemens Healthineers, Stryker Corporation, and Teleflex Incorporated.
The report includes an in-depth analysis of the Global Interventional Oncology Market, including market size and trends, product mix, Applications, and supplier analysis
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
